Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?

Heart Rhythm

Volumn 12, Issue 8, 2015, Pages 1807-1812

  Rohatgi, Ram K ^a   Bos, J Martijn ^a,b   Ackerman, Michael J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Attention deficit hyperactivity disorder; Long QT syndrome; Stimulant therapy

Indexed keywords

CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GENETIC SCREENING; GENOTYPE; HUMAN; INCIDENCE; LONG QT SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHEMICALLY INDUCED; COMORBIDITY; DRUG EFFECTS; HEART RATE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; HEART RATE; HUMANS; INCIDENCE; LONG QT SYNDROME; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84937524952     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2015.04.043     Document Type: Article

References (24)

1. PJ Schwartz, MJ Ackerman, AL George Jr, and AA. Wilde Impact of genetics on the clinical management of channelopathies J Am Coll Cardiol 62 2013 169 180
2. PJ Schwartz, and MJ. Ackerman The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy Eur Heart J 34 2013 3109 3116
3. MJ. Ackerman The long QT syndrome: ion channel diseases of the heart Mayo Clin Proc 73 1998 250 269
4. DM. Roden Clinical practice. Long-QT syndrome N Engl J Med 358 2008 169 176
5. AJ Moss, W Shimizu, AA Wilde, and et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene Circulation 115 2007 2481 2489
6. SG Priori, PJ Schwartz, C Napolitano, R Bloise, E Ronchetti, M Grillo, A Vicentini, C Spazzolini, J Nastoli, G Bottelli, R Folli, and D. Cappelletti Risk stratification in the long-QT syndrome N Engl J Med 348 2003 1866 1874
7. SN Visser, ML Danielson, RH Bitsko, JR Holbrook, MD Kogan, RM Ghandour, R Perou, and SJ. Blumberg Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011 J Am Acad Child Adolesc Psychiatry 53 2014 34 46 e32
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. 2013.
9. IM Loe, and HM. Feldman Academic and educational outcomes of children with ADHD J Pediatr Psychol 32 2007 643 654
10. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder Arch Gen Psychiatry 56 1999 1088 1096
11. Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting, February 9 and 10, 2006
12. SE. Nissen ADHD drugs and cardiovascular risk N Engl J Med 354 2006 1445 1448
13. VL Vetter, J Elia, C Erickson, S Berger, N Blum, K Uzark, and CL. Webb Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing Circulation 117 2008 2407 2423
14. PJ Schwartz, SG Priori, C Spazzolini, and et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias Circulation 103 2001 89 95
15. W Shimizu, and C. Antzelevitch Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes Circulation 98 1998 2314 2322
16. CredibleMeds. Available at: https://www.crediblemeds.org/. Accessed September 1, 2014.
17. M Wolraich, L Brown, RT Brown, and et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents Pediatrics 128 2011 1007 1022
18. S. Pliszka Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder J Am Acad Child Adolesc Psychiatry 46 2007 894 921
19. MV. Solanto Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration Behav Brain Res 94 1998 127 152
20. TE. Wilens Mechanism of action of agents used in attention-deficit/hyperactivity disorder J Clin Psychiatry 67 Suppl 8 2006 32 38
21. WO Cooper, LA Habel, CM Sox, and et al. ADHD drugs and serious cardiovascular events in children and young adults N Engl J Med 365 2011 1896 1904
22. AN Westover, and EA. Halm Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review BMC Cardiovasc Disord 12 2012 41
23. AG Winterstein, T Gerhard, P Kubilis, A Saidi, S Linden, S Crystal, J Zito, JJ Shuster, and M. Olfson Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study BMJ 345 2012 e4627
24. JN Johnson, and MJ. Ackerman Return to play? Athletes with congenital long QT syndrome Br J Sports Med 47 2013 28 33